Progenics Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted to review the New Drug Application (NDA) for AZEDRA in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors.  The FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).   “With no FDA-approved therapies for these rare tumors, AZEDRA h...